EP Patent

EP4228653A1 — Pharmaceutical formulations for treating diseases associated with voltage-gated sodium channels

Assigned to Xenon Pharmaceuticals Inc · Expires 2023-08-23 · 3y expired

What this patent protects

Provided herein are certain pharmaceutical compositions comprising (S)-4-(( 1 -benzylpyrrolidin-3 -yl)(methyl)amino)-2-fluoro-5-methyl-N-(thiazol-4-yl)benzenesulfonamide (Compound A), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable exci…

USPTO Abstract

Provided herein are certain pharmaceutical compositions comprising (S)-4-(( 1 -benzylpyrrolidin-3 -yl)(methyl)amino)-2-fluoro-5-methyl-N-(thiazol-4-yl)benzenesulfonamide (Compound A), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient. The pharmaceutical compositions can be present in form of an immediate release tablet, a granular formulation, a stable suspension oral dosage form or a multi-particulate sprinkle dosage form. Methods for the treatment of a disease or a condition associated with Naj4.6 activity, such as epilepsy, are described.

Drugs covered by this patent

Patent Metadata

Patent number
EP4228653A1
Jurisdiction
EP
Classification
—
Expires
2023-08-23
Drug substance claim
No
Drug product claim
No
Assignee
Xenon Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.